Short description
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
Description
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The company's research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California.
Last funding
Noaccess
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
San Diego, California, United States, North America
Founded on
January 1, 1992
Exited on
May 31, 1996
Went public on
May 31, 1996
Stock symbol
NBIX
Non-profit?
No
Acquired?
No
Employees count
1001-5000
Revenue range
$34056 - 789030
Sign in for full access
Investors
Blurry Noaccess
Sign in for full access
Founders
Errol De Souza, Larry Bock, Wylie Vale
Funding rounds count
2
Portfolio organisations count
Absolutely Noaccess, Cannot Access
Sign in for full access
Lead investments count
2
Exits count
Nopepepe, Noway Youcantaccess
Sign in for full access
IPO exits count
2